Breaking News, Collaborations & Alliances

Starton Therapeutics, Bend Partner to Advance STAR-LLD

New collaboration aims to optimize a proprietary oral sustained-release dosage form of lenalidomide.

Author Image

By: Charlie Sternberg

Associate Editor

Starton Therapeutics Inc., a clinical-stage biotechnology company, has entered into a collaboration agreement with Bend Bioscience, an innovation, science, and pharmaceutical services partner. Under this agreement, Bend will provide drug delivery R&D support and manufacturing capabilities for Starton’s lead candidate, STAR-LLD, a proprietary oral sustained-release dosage form of lenalidomide. While the branded lenalidomide product remains a cornerstone treatment for multiple myeloma, the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters